Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
March 13 2017 - 8:15AM
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage
biopharmaceutical company focused on developing therapies for
life-threatening rare genetic diseases, today announced Chief
Operating Officer, Jeffrey B. Davis, will present at the 29th
Annual ROTH Conference and the Oppenheimer 27th Annual
Healthcare Conference.
Event: The 29th Annual ROTH
ConferenceDate: Tuesday, March 14th
Time: 10:30 am PT / 1:30 pm
ETRoom: Yellow - Salon 6Location:
The Ritz-Carlton, Laguna Niguel, CA
Event: The Oppenheimer 27th Annual Healthcare
ConferenceDate: Tuesday, March 21st
Time: 4:30 pm ET
Room: Track 3Location: The Westin
New York Grand Central, NY Webcast:
https://www.veracast.com/webcasts/opco/healthcare2017/42114505926.cfm
Abeona Recent Highlights:
- March 8, 2017: Received Orphan Drug Designation in the EU for
EB-101 in Epidermolysis Bullosa
- February 17, 2017: Provided update from ABO-102 Sanfilippo type
A program (MPS IIIA) at WORLDSymposium ™ lysosomal storage
disorders conference
- 6 months post-injection (N=2): 63% +/- 0.5% reduction in the
disease-causing sugar (heparan sulfate GAG) in the central nervous
system
- Continued evidence of biopotency: reduced liver and spleen
volumes, decreased urinary GAGs
- Evidence for stabilization or improvement (average 60%) in
several Mullen subdomains
- Adaptive behavior ratings on the Vineland stabilized
- Improved raw scores on the Leiter-R non-verbal IQ
assessments
- Well-tolerated (N=4) through 650 days follow up with no Serious
Adverse Events
- February 1, 2017: Enrolled first high-dose subject in ABO-102
ongoing Phase 1/2 trial in MPS IIIA
- January 19, 2017: Received Orphan Drug Designation in the EU
for ABO-101 in MPS IIIB
- January 3, 2017: Received Orphan Drug Designation in the EU for
ABO-201 in juvenile Batten disease
About Abeona: Abeona
Therapeutics Inc. is a leading clinical-stage biopharmaceutical
company developing gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and
ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene
therapies for Sanfilippo syndrome (MPS IIIA and IIIB,
respectively). Abeona is also developing EB-101 (gene-corrected
skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB),
EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene
therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene
therapy for treatment of infantile Batten disease (INCL), and
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302
using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona has a
plasma-based protein therapy pipeline, including SDF Alpha™
(alpha-1 protease inhibitor) for inherited COPD, using its
proprietary SDF™ (Salt Diafiltration) ethanol-free process. For
more information, visit www.abeonatherapeutics.com.
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain
necessary regulatory approvals; the impact of changes in the
financial markets and global economic conditions; our belief that
initial signals of biopotency and clinical activity, which suggest
that ABO-102 successfully reached target tissues throughout the
body, including the central nervous system; our belief that the
data demonstrate an early and robust systemic delivery of ABO-102,
and the increased reductions in CNS GAG support our approach for
intravenous delivery for subjects with Sanfilippo syndromes, and
other risks as may be detailed from time to time in the Company's
Annual Reports on Form 10-K and other reports filed by the Company
with the Securities and Exchange Commission. The Company undertakes
no obligations to make any revisions to the forward-looking
statements contained in this release or to update them to reflect
events or circumstances occurring after the date of this release,
whether as a result of new information, future developments or
otherwise.
Investor Contact:Christine SilversteinVice
President, Investor RelationsAbeona Therapeutics Inc.+1
(212)-786-6212csilverstein@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024